69 results
424B3
ZVRA
Zevra Therapeutics Inc
10 Oct 23
Prospectus supplement
5:07pm
community, Acer has also established a pricing strategy that reflects Acer’s commitment to deliver innovative treatments that are responsibly priced
S-4/A
ZVRA
Zevra Therapeutics Inc
6 Oct 23
Registration of securities issued in business combination transactions (amended)
4:06pm
to deliver innovative treatments that are responsibly priced and accessible to those in need. As a result, Acer intends to price OLPRUVA™ competitively
S-4
ZVRA
Zevra Therapeutics Inc
28 Sep 23
Registration of securities issued in business combination transactions
9:25pm
commitment to deliver innovative treatments that are responsibly priced and accessible to those in need. As a result, Acer intends to price OLPRUVA™
8-K
EX-99.2
khbpmqtkf kmnns4zaf1
16 May 22
KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline
8:40am
8-K
vapbpcwq0mcstd0fxao
16 Mar 22
KemPharm team provided development and regulatory services to Corium pursuant to a master development services agreement
8:32am
8-K
EX-99.1
i1q8aw 3j6vbgkg62m
16 Mar 22
KemPharm team provided development and regulatory services to Corium pursuant to a master development services agreement
8:32am
424B3
0e35 9kqx
10 Nov 21
Prospectus supplement
5:19pm
424B3
88kr1wjzaz5q4j a2k
10 Nov 21
Prospectus supplement
5:15pm
8-K
EX-99.1
y5l36rziq9cg8oo
10 Nov 21
KemPharm Reports Third Quarter 2021 Financial Results and Corporate Updates
4:12pm
424B3
x0wapyjit1wut8 rlod
16 Aug 21
Prospectus supplement
12:00am
424B3
utd 6rzcmov
21 Jul 21
Prospectus supplement
8:47am
8-K
EX-99.1
1podq7oxt4
21 Jul 21
Other Events
8:46am